# Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

> **NCT03405935** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 86 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT03405935
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-11-20
- **Final completion:** 2020-05-29
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03405935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03405935, "Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03405935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*